BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Shares Bought by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. lifted its position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 1.6% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,423,508 shares of the biotechnology company's stock after acquiring an additional 21,880 shares during the period. Charles Schwab Investment Management Inc. owned 0.75% of BioMarin Pharmaceutical worth $93,567,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Wealth Enhancement Advisory Services LLC increased its holdings in shares of BioMarin Pharmaceutical by 64.1% in the third quarter. Wealth Enhancement Advisory Services LLC now owns 5,861 shares of the biotechnology company's stock valued at $412,000 after purchasing an additional 2,289 shares during the period. Janney Montgomery Scott LLC boosted its position in BioMarin Pharmaceutical by 102.1% in the third quarter. Janney Montgomery Scott LLC now owns 11,700 shares of the biotechnology company's stock valued at $822,000 after buying an additional 5,911 shares during the last quarter. AIA Group Ltd increased its holdings in BioMarin Pharmaceutical by 15.4% in the 3rd quarter. AIA Group Ltd now owns 3,435 shares of the biotechnology company's stock worth $241,000 after buying an additional 458 shares during the period. Covestor Ltd raised its position in BioMarin Pharmaceutical by 336.4% during the 3rd quarter. Covestor Ltd now owns 1,030 shares of the biotechnology company's stock worth $72,000 after buying an additional 794 shares during the last quarter. Finally, Crossmark Global Holdings Inc. raised its position in BioMarin Pharmaceutical by 20.6% during the 3rd quarter. Crossmark Global Holdings Inc. now owns 13,322 shares of the biotechnology company's stock worth $937,000 after buying an additional 2,277 shares during the last quarter. Hedge funds and other institutional investors own 98.71% of the company's stock.

Remove Ads

Insider Buying and Selling

In other BioMarin Pharmaceutical news, CAO Erin Burkhart sold 1,344 shares of the firm's stock in a transaction on Monday, February 24th. The stock was sold at an average price of $68.38, for a total value of $91,902.72. Following the completion of the sale, the chief accounting officer now directly owns 13,105 shares of the company's stock, valued at $896,119.90. This trade represents a 9.30 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 1.85% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of research firms recently issued reports on BMRN. StockNews.com upgraded shares of BioMarin Pharmaceutical from a "buy" rating to a "strong-buy" rating in a research report on Monday. Scotiabank upped their target price on BioMarin Pharmaceutical from $78.00 to $80.00 and gave the stock a "sector perform" rating in a research note on Thursday, February 20th. Bank of America lifted their price target on BioMarin Pharmaceutical from $99.00 to $103.00 and gave the company a "buy" rating in a research report on Thursday, February 20th. Citigroup upped their price objective on BioMarin Pharmaceutical from $81.00 to $82.00 and gave the stock a "neutral" rating in a research report on Thursday, February 20th. Finally, Oppenheimer raised shares of BioMarin Pharmaceutical from a "market perform" rating to an "outperform" rating and set a $98.00 target price for the company in a report on Monday, February 24th. Seven equities research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, BioMarin Pharmaceutical has an average rating of "Moderate Buy" and an average target price of $94.00.

BioMarin Pharmaceutical Price Performance

Shares of BioMarin Pharmaceutical stock traded up $0.04 during trading hours on Thursday, reaching $70.58. 533,448 shares of the company's stock were exchanged, compared to its average volume of 1,773,540. The business has a fifty day moving average of $66.08 and a two-hundred day moving average of $69.09. The company has a quick ratio of 2.62, a current ratio of 5.33 and a debt-to-equity ratio of 0.11. The company has a market capitalization of $13.47 billion, a P/E ratio of 32.08, a price-to-earnings-growth ratio of 0.61 and a beta of 0.33. BioMarin Pharmaceutical Inc. has a 1 year low of $60.63 and a 1 year high of $94.85.

BioMarin Pharmaceutical (NASDAQ:BMRN - Get Free Report) last announced its quarterly earnings data on Wednesday, February 19th. The biotechnology company reported $0.72 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.54 by $0.18. BioMarin Pharmaceutical had a net margin of 14.96% and a return on equity of 9.91%. The company had revenue of $747.31 million during the quarter, compared to analysts' expectations of $711.05 million. As a group, research analysts predict that BioMarin Pharmaceutical Inc. will post 3.15 earnings per share for the current fiscal year.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.